Clinical value of geriatric nutritional risk index and pan-immune-inflammation value in locally advanced gastric cancer receiving neoadjuvant chemotherapy

Table 5 Relationship between clinical characteristics and the different score group, n (%)/mean ± SD

Clinical characteristics	GNRI-PIV score				P value
	Total (n = 147)	0 (n = 82)	1 (n = 53)	2 (n = 12)
Gender					0.274
Male	107 (72.79)	64 (78.05)	35 (66.04)	8 (66.67)
Female	40 (27.21)	18 (21.95)	18 (33.96)	4 (33.33)
Age					0.555
< 65	101 (68.71)	59 (71.95)	35 (66.04)	7 (58.33)
≥ 65	46 (31.29)	23 (28.05)	18 (33.96)	5 (41.67)
BMI					< 0.001
< 25	97 (65.99)	40 (48.78)	46 (86.79)	11 (91.67)
≥ 25	50 (34.01)	42 (51.22)	7 (13.21)	1 (8.33)
Smoking history					0.935
No	67 (45.58)	37 (45.12)	25 (47.17)	5 (41.67)
Yes	80 (54.42)	45 (54.88)	28 (52.83)	7 (58.33)
Drinking history					0.295
No	85 (57.82)	43 (52.44)	35 (66.04)	7 (58.33)
Yes	62 (42.18)	39 (47.56)	18 (33.96)	5 (41.67)
Diabetes					0.635
No	122 (82.99)	66 (80.49)	46 (86.79)	10 (83.33)
Yes	25 (17.01)	16 (19.51)	7 (13.21)	2 (16.67)
Hypertension					0.285
No	103 (70.07)	59 (71.95)	38 (71.7)	6 (50)
Yes	44 (29.93)	23 (28.05)	15 (28.3)	6 (50)
Location					0.64
1/3 lower	89 (60.54)	46 (56.1)	35 (66.04)	8 (66.67)
1/3 middle	32 (21.77)	19 (23.17)	10 (18.87)	3 (25)
1/3 upper	11 (7.48)	9 (10.98)	2 (3.77)	0 (0)
Total	15 (10.2)	8 (9.76)	6 (11.32)	1 (8.33)
Clinical T stage					0.489
T2	15 (10.2)	10 (12.2)	4 (7.55)	1 (8.33)
T3	65 (44.22)	40 (48.78)	20 (37.74)	5 (41.67)
T4	67 (45.58)	32 (39.02)	29 (54.72)	6 (50)
Clinical N stage					0.744
N-	37 (25.17)	22 (26.83)	13 (24.53)	2 (16.67)
N+	110 (74.83)	60 (73.17)	40 (75.47)	10 (83.33)
Clinical stage					0.028
Stage 2	54 (36.73)	37 (45.12)	12 (22.64)	5 (41.67)
Stage 3	93 (63.27)	45 (54.88)	41 (77.36)	7 (58.33)
CEA, ng/mL	3.30 (3.52)	3.05 (2.62)	3.70 (4.79)	3.20 (2.10)	0.883
CA19-9, U/mL	16.59 (20.63)	15.11 (18.56)	19.56 (24.91)	13.62 (10.52)	0.807
hsCRP, mg/L	2.56 (4.75)	2.48 (4.92)	2.94 (4.97)	1.36 (1.12)	0.416
NRS2002 score					0.002
< 3	103 (70.07)	67 (81.71)	30 (56.6)	6 (50)
≥ 3	44 (29.93)	15 (18.29)	23 (43.4)	6 (50)
Vascular invasion					0.223
No	99 (67.35)	59 (71.95)	31 (58.49)	9 (75)
Yes	48 (32.65)	23 (28.05)	22 (41.51)	3 (25)
Perineural invasion					0.401
No	108 (73.47)	60 (73.17)	41 (77.36)	7 (58.33)
Yes	39 (26.53)	22 (26.83)	12 (22.64)	5 (41.67)
Pathological stage					0.347
PCR	21 (14.29)	12 (14.63)	8 (15.09)	1 (8.33)
1	53 (36.05)	35 (42.68)	16 (30.19)	2 (16.67)
2	35 (23.81)	18 (21.95)	12 (22.64)	5 (41.67)
3	38 (25.85)	17 (20.73)	17 (32.08)	4 (33.33)
CAP					0.044
CAP 0-1	50 (34.01)	35 (42.68)	12 (22.64)	3 (25)
CAP 2-3	97 (65.99)	47 (57.32)	41 (77.36)	9 (75)
Complication					0.035
No	98 (66.67)	62 (75.61)	29 (54.72)	7 (58.33)
Yes	49 (33.33)	20 (24.39)	24 (45.28)	5 (41.67)

BMI: Body mass index; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; hsCRP: High-sensitivity C-reactive protein; NRS2002: Nutritional Risk Screening 2002; PCR: Pathological complete response; CAP: College of American Pathologists; GNRI: Geriatric nutritional risk index; PIV: Pan-immune-inflammation value.